NCT04535817View on ClinicalTrials.gov

Xolair Interventional Study in ASD Patients With Comorbid Atopy

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

January 1, 2022

Conditions
Autism Spectrum DisorderAtopy
Interventions
DRUG

Omalizumab Injection [Xolair]

300mg via 2 subcutaneous injections every 4 weeks

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04535817 - Xolair Interventional Study in ASD Patients With Comorbid Atopy | Biotech Hunter | Biotech Hunter